President & CEO of Ultragenyx Pharmaceutical Inc (30-Year Financial, Insider Trades) Emil D Kakkis (insider trades) bought 5,000 shares of RARE on 09/11/2019 at an average price of $43.63 a share. The total cost of this purchase was $218,150.
Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases. Ultragenyx Pharmaceutical Inc has a market cap of $2.58 billion; its shares were traded at around $44.80 with and P/S ratio of 34.07. GuruFocus has detected 1 severe warning sign with Ultragenyx Pharmaceutical Inc. .
CEO Recent Trades:
- President & CEO Emil D Kakkis bought 5,000 shares of RARE stock on 09/11/2019 at the average price of $43.63. The price of the stock has increased by 2.68% since.
For the complete insider trading history of RARE, click here
.This article first appeared on GuruFocus.
- Warning! GuruFocus has detected 1 Warning Sign with RARE. Click here to check it out.
- RARE 15-Year Financial Data
- The intrinsic value of RARE
- Peter Lynch Chart of RARE